Trial Profile
Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs BI 730357 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 11 Jun 2021 Status changed from active, no longer recruiting to completed.
- 23 Feb 2021 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2021 Planned End Date changed from 20 Jul 2021 to 4 Jun 2021.